Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 65

1.

NET-02 trial protocol: a multicentre, randomised, parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (NEC).

Craig Z, Swain J, Batman E, Wadsley J, Reed N, Faluyi O, Cave J, Sharma R, Chau I, Wall L, Lamarca A, Hubner R, Mansoor W, Sarker D, Meyer T, Cairns DA, Howard H, Valle JW, McNamara MG.

BMJ Open. 2020 Feb 5;10(2):e034527. doi: 10.1136/bmjopen-2019-034527.

2.

BRAF and DIS3 Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma.

Boyle EM, Ashby C, Tytarenko R, Deshpande S, Wang Y, Sawyer J, Tian E, Johnson S, Rutherford MW, Wardell CP, Bauer MA, Thanendrarajan S, Schinke C, Zangari M, van Rhee F, Wang H, Rosenthal A, Hoering A, Flynt E, Thakurta A, Dumontet C, Facon T, Cairns DA, Jackson GH, Barlogie B, Davies FE, Morgan GJ, Walker BA.

Clin Cancer Res. 2020 Jan 27. pii: clincanres.1507.2019. doi: 10.1158/1078-0432.CCR-19-1507. [Epub ahead of print]

PMID:
31988198
3.

Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial.

Jackson GH, Davies FE, Pawlyn C, Cairns DA, Striha A, Collett C, Waterhouse A, Jones JR, Kishore B, Garg M, Williams CD, Karunanithi K, Lindsay J, Wilson JN, Jenner MW, Cook G, Kaiser MF, Drayson MT, Owen RG, Russell NH, Gregory WM, Morgan GJ; UK NCRI Haematological Oncology Clinical Studies Group.

Lancet Haematol. 2019 Dec;6(12):e616-e629. doi: 10.1016/S2352-3026(19)30167-X. Epub 2019 Oct 14.

4.

Optimising pacemaker therapy and medical therapy in pacemaker patients for heart failure: protocol for the OPT-PACE randomised controlled trial.

Paton MF, Gierula J, Jamil HA, Lowry JE, Byrom R, Gillott RG, Chumun H, Cubbon RM, Cairns DA, Stocken DD, Kearney MT, Witte KK.

BMJ Open. 2019 Jul 17;9(7):e028613. doi: 10.1136/bmjopen-2018-028613.

5.

Patient-Reported Outcome Results From the Open-Label, Randomized Phase III Myeloma X Trial Evaluating Salvage Autologous Stem-Cell Transplantation in Relapsed Multiple Myeloma.

Ahmedzai SH, Snowden JA, Ashcroft AJ, Cairns DA, Williams C, Hockaday A, Cavenagh JD, Ademokun D, Tholouli E, Allotey D, Dhanapal V, Jenner M, Yong K, Cavet J, Hunter H, Bird JM, Pratt G, Parrish C, Brown JM, Morris TCM, Cook G; National Cancer Research Institute Haemato-Oncology Clinical Studies Group.

J Clin Oncol. 2019 Jul 1;37(19):1617-1628. doi: 10.1200/JCO.18.01006. Epub 2019 Apr 10.

6.

A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): a development and validation study.

Cook G, Royle KL, Pawlyn C, Hockaday A, Shah V, Kaiser MF, Brown SR, Gregory WM, Child JA, Davies FE, Morgan GJ, Cairns DA, Jackson GH.

Lancet Haematol. 2019 Mar;6(3):e154-e166. doi: 10.1016/S2352-3026(18)30220-5. Epub 2019 Feb 6.

7.

Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patients.

Jones JR, Weinhold N, Ashby C, Walker BA, Wardell C, Pawlyn C, Rasche L, Melchor L, Cairns DA, Gregory WM, Johnson D, Begum DB, Ellis S, Sherborne AL, Cook G, Kaiser MF, Drayson MT, Owen RG, Jackson GH, Davies FE, Greaves M, Morgan GJ; NCRI Haemato-Oncology CSG.

Haematologica. 2019 Jul;104(7):1440-1450. doi: 10.3324/haematol.2018.202200. Epub 2019 Feb 7.

8.

The impact of cytogenetics on duration of response and overall survival in patients with relapsed multiple myeloma (long-term follow-up results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial.

Cook G, Royle KL, O'Connor S, Cairns DA, Ashcroft AJ, Williams CD, Hockaday A, Cavenagh JD, Snowden JA, Ademokun D, Tholouli E, Andrews VE, Jenner M, Parrish C, Yong K, Cavet J, Hunter H, Bird JM, Pratt G, Drayson MT, Brown JM, Morris TCM; National Cancer Research Institute Haemato-oncology Clinical Studies Group.

Br J Haematol. 2019 May;185(3):450-467. doi: 10.1111/bjh.15782. Epub 2019 Feb 6.

9.

Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial.

Jackson GH, Davies FE, Pawlyn C, Cairns DA, Striha A, Collett C, Hockaday A, Jones JR, Kishore B, Garg M, Williams CD, Karunanithi K, Lindsay J, Jenner MW, Cook G, Russell NH, Kaiser MF, Drayson MT, Owen RG, Gregory WM, Morgan GJ; UK NCRI Haemato-oncology Clinical Studies Group.

Lancet Oncol. 2019 Jan;20(1):57-73. doi: 10.1016/S1470-2045(18)30687-9. Epub 2018 Dec 14.

10.

Identification and validation of DOCK4 as a potential biomarker for risk of bone metastasis development in patients with early breast cancer.

Westbrook JA, Wood SL, Cairns DA, McMahon K, Gahlaut R, Thygesen H, Shires M, Roberts S, Marshall H, Oliva MR, Dunning MJ, Hanby AM, Selby PJ, Speirs V, Mavria G, Coleman RE, Brown JE.

J Pathol. 2019 Mar;247(3):381-391. doi: 10.1002/path.5197. Epub 2019 Jan 25.

11.

Subclonal TP53 copy number is associated with prognosis in multiple myeloma.

Shah V, Johnson DC, Sherborne AL, Ellis S, Aldridge FM, Howard-Reeves J, Begum F, Price A, Kendall J, Chiecchio L, Savola S, Jenner MW, Drayson MT, Owen RG, Gregory WM, Morgan GJ, Davies FE, Houlston RS, Cook G, Cairns DA, Jackson G, Kaiser MF; National Cancer Research Institute Haematology Clinical Studies Group.

Blood. 2018 Dec 6;132(23):2465-2469. doi: 10.1182/blood-2018-06-857250. Epub 2018 Oct 29.

12.

Maintenance Treatment and Survival in Patients With Myeloma: A Systematic Review and Network Meta-analysis.

Gay F, Jackson G, Rosiñol L, Holstein SA, Moreau P, Spada S, Davies F, Lahuerta JJ, Leleu X, Bringhen S, Evangelista A, Hulin C, Panzani U, Cairns DA, Di Raimondo F, Macro M, Liberati AM, Pawlyn C, Offidani M, Spencer A, Hájek R, Terpos E, Morgan GJ, Bladé J, Sonneveld P, San-Miguel J, McCarthy PL, Ludwig H, Boccadoro M, Mateos MV, Attal M.

JAMA Oncol. 2018 Oct 1;4(10):1389-1397. doi: 10.1001/jamaoncol.2018.2961.

13.

Methods for the evaluation of biomarkers in patients with kidney and liver diseases: multicentre research programme including ELUCIDATE RCT.

Selby PJ, Banks RE, Gregory W, Hewison J, Rosenberg W, Altman DG, Deeks JJ, McCabe C, Parkes J, Sturgeon C, Thompson D, Twiddy M, Bestall J, Bedlington J, Hale T, Dinnes J, Jones M, Lewington A, Messenger MP, Napp V, Sitch A, Tanwar S, Vasudev NS, Baxter P, Bell S, Cairns DA, Calder N, Corrigan N, Del Galdo F, Heudtlass P, Hornigold N, Hulme C, Hutchinson M, Lippiatt C, Livingstone T, Longo R, Potton M, Roberts S, Sim S, Trainor S, Welberry Smith M, Neuberger J, Thorburn D, Richardson P, Christie J, Sheerin N, McKane W, Gibbs P, Edwards A, Soomro N, Adeyoju A, Stewart GD, Hrouda D.

Southampton (UK): NIHR Journals Library; 2018 Jun.

14.

Quality of life during and following sequential treatment of previously untreated patients with multiple myeloma: findings of the Medical Research Council Myeloma IX randomised study.

Royle KL, Gregory WM, Cairns DA, Bell SE, Cook G, Owen RG, Drayson MT, Davies FE, Jackson GH, Morgan GJ, Child JA.

Br J Haematol. 2018 Sep;182(6):816-829. doi: 10.1111/bjh.15459. Epub 2018 Jul 9.

15.

The future for diagnostic tests of acute kidney injury in critical care: evidence synthesis, care pathway analysis and research prioritisation.

Hall PS, Mitchell ED, Smith AF, Cairns DA, Messenger M, Hutchinson M, Wright J, Vinall-Collier K, Corps C, Hamilton P, Meads D, Lewington A.

Health Technol Assess. 2018 May;22(32):1-274. doi: 10.3310/hta22320. Review.

16.

The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd [UK-MRA Myeloma XII] trial): study protocol for a Phase III randomised controlled trial.

Striha A, Ashcroft AJ, Hockaday A, Cairns DA, Boardman K, Jacques G, Williams C, Snowden JA, Garg M, Cavenagh J, Yong K, Drayson MT, Owen R, Cook M, Cook G.

Trials. 2018 Mar 7;19(1):169. doi: 10.1186/s13063-018-2524-8.

17.

Rate-Response Programming Tailored to the Force-Frequency Relationship Improves Exercise Tolerance in Chronic Heart Failure.

Gierula J, Paton MF, Lowry JE, Jamil HA, Byrom R, Drozd M, Garnham JO, Cubbon RM, Cairns DA, Kearney MT, Witte KK.

JACC Heart Fail. 2018 Feb;6(2):105-113. doi: 10.1016/j.jchf.2017.09.018. Epub 2017 Dec 6.

18.

Response comparison of multiple myeloma and monoclonal gammopathy of undetermined significance to the same anti-myeloma therapy: a retrospective cohort study.

Campbell JP, Heaney JLJ, Pandya S, Afzal Z, Kaiser M, Owen R, Child JA, Cairns DA, Gregory W, Morgan GJ, Jackson GH, Bunce CM, Drayson MT.

Lancet Haematol. 2017 Dec;4(12):e584-e594. doi: 10.1016/S2352-3026(17)30209-0. Epub 2017 Nov 13.

19.

Cardiac resynchronization therapy outcomes in patients with chronic heart failure: cardiac resynchronization therapy with pacemaker versus cardiac resynchronization therapy with defibrillator.

Drozd M, Gierula J, Lowry JE, Paton MF, Joy E, Jamil HA, Cubbon RM, Kearney MT, Cairns DA, Witte KK.

J Cardiovasc Med (Hagerstown). 2017 Dec;18(12):962-967. doi: 10.2459/JCM.0000000000000584.

PMID:
29045311
20.

Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients.

Shah V, Sherborne AL, Walker BA, Johnson DC, Boyle EM, Ellis S, Begum DB, Proszek PZ, Jones JR, Pawlyn C, Savola S, Jenner MW, Drayson MT, Owen RG, Houlston RS, Cairns DA, Gregory WM, Cook G, Davies FE, Jackson GH, Morgan GJ, Kaiser MF.

Leukemia. 2018 Jan;32(1):102-110. doi: 10.1038/leu.2017.179. Epub 2017 Jun 6.

21.

Diagnosis and monitoring for light chain only and oligosecretory myeloma using serum free light chain tests.

Heaney JLJ, Campbell JP, Griffin AE, Birtwistle J, Shemar M, Child JA, Gregory WM, Cairns DA, Morgan G, Jackson G, Drayson MT.

Br J Haematol. 2017 Jul;178(2):220-230. doi: 10.1111/bjh.14753. Epub 2017 Jun 1.

22.

Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial.

Jones JR, Cairns DA, Gregory WM, Collett C, Pawlyn C, Sigsworth R, Striha A, Henderson R, Kaiser MF, Jenner M, Cook G, Russell NH, Williams C, Pratt G, Kishore B, Lindsay J, Drayson MT, Davies FE, Boyd KD, Owen RG, Jackson GH, Morgan GJ.

Blood Cancer J. 2016 Dec 9;6(12):e506. doi: 10.1038/bcj.2016.114.

23.

The Spectrum and Clinical Impact of Epigenetic Modifier Mutations in Myeloma.

Pawlyn C, Kaiser MF, Heuck C, Melchor L, Wardell CP, Murison A, Chavan SS, Johnson DC, Begum DB, Dahir NM, Proszek PZ, Cairns DA, Boyle EM, Jones JR, Cook G, Drayson MT, Owen RG, Gregory WM, Jackson GH, Barlogie B, Davies FE, Walker BA, Morgan GJ.

Clin Cancer Res. 2016 Dec 1;22(23):5783-5794. Epub 2016 May 27.

24.

Reply: Potential Risk of Increased Risk of Falls Associated With High Doses of Vitamin D Treatment.

Byrom R, Cairns DA, Witte KK.

J Am Coll Cardiol. 2016 Oct 18;68(16):1819-1820. doi: 10.1016/j.jacc.2016.07.759. No abstract available.

25.

Effect of Care Guided by Cardiovascular Magnetic Resonance, Myocardial Perfusion Scintigraphy, or NICE Guidelines on Subsequent Unnecessary Angiography Rates: The CE-MARC 2 Randomized Clinical Trial.

Greenwood JP, Ripley DP, Berry C, McCann GP, Plein S, Bucciarelli-Ducci C, Dall'Armellina E, Prasad A, Bijsterveld P, Foley JR, Mangion K, Sculpher M, Walker S, Everett CC, Cairns DA, Sharples LD, Brown JM; CE-MARC 2 Investigators.

JAMA. 2016 Sep 13;316(10):1051-60. doi: 10.1001/jama.2016.12680.

26.

The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial.

Cook G, Ashcroft AJ, Cairns DA, Williams CD, Brown JM, Cavenagh JD, Snowden JA, Parrish C, Yong K, Cavet J, Hunter H, Bird JM, Pratt G, Chown S, Heartin E, O'Connor S, Drayson MT, Hockaday A, Morris TC; National Cancer Research Institute Haemato-oncology Clinical Studies Group.

Lancet Haematol. 2016 Jul;3(7):e340-51. doi: 10.1016/S2352-3026(16)30049-7.

27.

Chronotropic Incompetence Does Not Limit Exercise Capacity in Chronic Heart Failure.

Jamil HA, Gierula J, Paton MF, Byrom R, Lowry JE, Cubbon RM, Cairns DA, Kearney MT, Witte KK.

J Am Coll Cardiol. 2016 Apr 26;67(16):1885-96. doi: 10.1016/j.jacc.2016.02.042.

28.

Performance of 2014 NICE defibrillator implantation guidelines in heart failure risk stratification.

Cubbon RM, Witte KK, Kearney LC, Gierula J, Byrom R, Paton M, Sengupta A, Patel PA, Mn Walker A, Cairns DA, Rajwani A, Hall AS, Sapsford RJ, Kearney MT.

Heart. 2016 May 15;102(10):735-40. doi: 10.1136/heartjnl-2015-308939. Epub 2016 Feb 8.

29.

Stem Cell Harvesting after Bortezomib-Based Reinduction for Myeloma Relapsing after Autologous Transplantation: Results from the British Society of Blood and Marrow Transplantation/United Kingdom Myeloma Forum Myeloma X (Intensive) Trial.

Parrish C, Morris CTCM, Williams CD, Cairns DA, Cavenagh J, Snowden JA, Ashcroft J, Cavet J, Hunter H, Bird JM, Chalmers A, Brown JM, Yong K, Schey S, Chown S, Cook G; National Cancer Research Institute Haemato-Oncology Clinical Studies Group.

Biol Blood Marrow Transplant. 2016 Jun;22(6):1009-1016. doi: 10.1016/j.bbmt.2016.01.016. Epub 2016 Jan 28.

30.

CAPG and GIPC1: Breast Cancer Biomarkers for Bone Metastasis Development and Treatment.

Westbrook JA, Cairns DA, Peng J, Speirs V, Hanby AM, Holen I, Wood SL, Ottewell PD, Marshall H, Banks RE, Selby PJ, Coleman RE, Brown JE.

J Natl Cancer Inst. 2016 Jan 12;108(4). doi: 10.1093/jnci/djv360. Print 2016 Apr. Erratum in: J Natl Cancer Inst. 2016 Mar;108(3). pii: djw017. doi: 10.1093/jnci/djw017.

31.

miR-17-92 fine-tunes MYC expression and function to ensure optimal B cell lymphoma growth.

Mihailovich M, Bremang M, Spadotto V, Musiani D, Vitale E, Varano G, Zambelli F, Mancuso FM, Cairns DA, Pavesi G, Casola S, Bonaldi T.

Nat Commun. 2015 Nov 10;6:8725. doi: 10.1038/ncomms9725.

32.

Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma.

Walker BA, Boyle EM, Wardell CP, Murison A, Begum DB, Dahir NM, Proszek PZ, Johnson DC, Kaiser MF, Melchor L, Aronson LI, Scales M, Pawlyn C, Mirabella F, Jones JR, Brioli A, Mikulasova A, Cairns DA, Gregory WM, Quartilho A, Drayson MT, Russell N, Cook G, Jackson GH, Leleu X, Davies FE, Morgan GJ.

J Clin Oncol. 2015 Nov 20;33(33):3911-20. doi: 10.1200/JCO.2014.59.1503. Epub 2015 Aug 17.

33.

APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma.

Walker BA, Wardell CP, Murison A, Boyle EM, Begum DB, Dahir NM, Proszek PZ, Melchor L, Pawlyn C, Kaiser MF, Johnson DC, Qiang YW, Jones JR, Cairns DA, Gregory WM, Owen RG, Cook G, Drayson MT, Jackson GH, Davies FE, Morgan GJ.

Nat Commun. 2015 Apr 23;6:6997. doi: 10.1038/ncomms7997.

34.

An analysis of the impact of pre-analytical factors on the urine proteome: Sample processing time, temperature, and proteolysis.

Hepburn S, Cairns DA, Jackson D, Craven RA, Riley B, Hutchinson M, Wood S, Smith MW, Thompson D, Banks RE.

Proteomics Clin Appl. 2015 Jun;9(5-6):507-21. doi: 10.1002/prca.201400079. Epub 2015 Feb 26.

35.

Statistical issues in the design and planning of proteomic profiling experiments.

Cairns DA.

Methods Mol Biol. 2015;1243:223-36. doi: 10.1007/978-1-4939-1872-0_13.

PMID:
25384749
36.

High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial.

Cook G, Williams C, Brown JM, Cairns DA, Cavenagh J, Snowden JA, Ashcroft AJ, Fletcher M, Parrish C, Yong K, Cavet J, Hunter H, Bird JM, Chalmers A, O'Connor S, Drayson MT, Morris TC; National Cancer Research Institute Haemato-oncology Clinical Studies Group.

Lancet Oncol. 2014 Jul;15(8):874-85. doi: 10.1016/S1470-2045(14)70245-1. Epub 2014 Jun 16. Erratum in: Lancet Oncol. 2014 Aug;15(9):e365. Dosage error in article text.

PMID:
24948586
37.

Methylation-specific multiplex ligation-dependent probe amplification identifies promoter methylation events associated with survival in glioblastoma.

Rankeillor KL, Cairns DA, Loughrey C, Short SC, Chumas P, Ismail A, Chakrabarty A, Lawler SE, Roberts P.

J Neurooncol. 2014 Apr;117(2):243-51. doi: 10.1007/s11060-014-1372-y. Epub 2014 Feb 20.

PMID:
24554053
38.

Biomarkers and response to bevacizumab--response.

Collinson F, Hutchinson M, Craven RA, Cairns DA, Alexandre Z, Wind TC, Gahir N, Messenger MP, Jackson S, Thompson D, Adusei C, Ledermann J, Hall G, Jayson GC, Selby PJ, Banks RE.

Clin Cancer Res. 2014 Feb 15;20(4):1058. doi: 10.1158/1078-0432.CCR-13-3269. No abstract available.

39.

Predicting response to bevacizumab in ovarian cancer: a panel of potential biomarkers informing treatment selection.

Collinson F, Hutchinson M, Craven RA, Cairns DA, Zougman A, Wind TC, Gahir N, Messenger MP, Jackson S, Thompson D, Adusei C, Ledermann JA, Hall G, Jayson GC, Selby PJ, Banks RE.

Clin Cancer Res. 2013 Sep 15;19(18):5227-39. doi: 10.1158/1078-0432.CCR-13-0489. Epub 2013 Aug 9.

40.

Serum aminoacylase-1 is a novel biomarker with potential prognostic utility for long-term outcome in patients with delayed graft function following renal transplantation.

Welberry Smith MP, Zougman A, Cairns DA, Wilson M, Wind T, Wood SL, Thompson D, Messenger MP, Mooney A, Selby PJ, Lewington AJ, Banks RE.

Kidney Int. 2013 Dec;84(6):1214-25. doi: 10.1038/ki.2013.200. Epub 2013 Jun 5.

41.

Proteomic analysis of formalin-fixed paraffin-embedded renal tissue samples by label-free MS: assessment of overall technical variability and the impact of block age.

Craven RA, Cairns DA, Zougman A, Harnden P, Selby PJ, Banks RE.

Proteomics Clin Appl. 2013 Apr;7(3-4):273-82. doi: 10.1002/prca.201200065. Epub 2013 Mar 6.

42.

Retinoic acid-induced protein 3: identification and characterisation of a novel prognostic colon cancer biomarker.

Zougman A, Hutchins GG, Cairns DA, Verghese E, Perry SL, Jayne DG, Selby PJ, Banks RE.

Eur J Cancer. 2013 Jan;49(2):531-9. doi: 10.1016/j.ejca.2012.07.031. Epub 2012 Sep 26.

PMID:
23021913
43.

NuMA overexpression in epithelial ovarian cancer.

Brüning-Richardson A, Bond J, Alsiary R, Richardson J, Cairns DA, McCormac L, Hutson R, Burns PA, Wilkinson N, Hall GD, Morrison EE, Bell SM.

PLoS One. 2012;7(6):e38945. doi: 10.1371/journal.pone.0038945. Epub 2012 Jun 14.

44.

A pilot study to investigate the potential of mass spectrometry profiling in the discovery of novel serum markers in chronic renal disease.

Thompson D, Develter W, Cairns DA, Barrett JH, Perkins DA, Stanley AJ, Mooney A, Selby PJ, Banks RE.

Proteomics Clin Appl. 2011 Oct;5(9-10):523-31. doi: 10.1002/prca.201100009. Epub 2011 Sep 7.

PMID:
21833999
45.

A systematic analysis of the effects of increasing degrees of serum immunodepletion in terms of depth of coverage and other key aspects in top-down and bottom-up proteomic analyses.

Smith MP, Wood SL, Zougman A, Ho JT, Peng J, Jackson D, Cairns DA, Lewington AJ, Selby PJ, Banks RE.

Proteomics. 2011 Jun;11(11):2222-35. doi: 10.1002/pmic.201100005. Epub 2011 May 5.

46.

ASPM and microcephalin expression in epithelial ovarian cancer correlates with tumour grade and survival.

Brüning-Richardson A, Bond J, Alsiary R, Richardson J, Cairns DA, McCormack L, Hutson R, Burns P, Wilkinson N, Hall GD, Morrison EE, Bell SM.

Br J Cancer. 2011 May 10;104(10):1602-10. doi: 10.1038/bjc.2011.117. Epub 2011 Apr 19.

47.

Statistical issues in quality control of proteomic analyses: good experimental design and planning.

Cairns DA.

Proteomics. 2011 Mar;11(6):1037-48. doi: 10.1002/pmic.201000579. Epub 2011 Feb 7. Review.

PMID:
21298792
48.

Initial development and validation of a novel extraction method for quantitative mining of the formalin-fixed, paraffin-embedded tissue proteome for biomarker investigations.

Nirmalan NJ, Hughes C, Peng J, McKenna T, Langridge J, Cairns DA, Harnden P, Selby PJ, Banks RE.

J Proteome Res. 2011 Feb 4;10(2):896-906. doi: 10.1021/pr100812d. Epub 2010 Dec 23.

49.

The prognostic and predictive value of CA-125 regression during neoadjuvant chemotherapy for advanced ovarian or primary peritoneal carcinoma.

Vasudev NS, Trigonis I, Cairns DA, Hall GD, Jackson DP, Broadhead T, Buxton J, Hutson R, Nugent D, Perren TJ.

Arch Gynecol Obstet. 2011 Jul;284(1):221-7. doi: 10.1007/s00404-010-1655-2. Epub 2010 Aug 29.

50.

Association of serum amyloid A protein and peptide fragments with prognosis in renal cancer.

Wood SL, Rogers M, Cairns DA, Paul A, Thompson D, Vasudev NS, Selby PJ, Banks RE.

Br J Cancer. 2010 Jun 29;103(1):101-11. doi: 10.1038/sj.bjc.6605720. Epub 2010 Jun 8.

Supplemental Content

Loading ...
Support Center